In July 2013 lurasidone received approval for bipolar I depression.[8][9] Few available atypical antipsychotics are known to possess antidepressant efficacy in bipolar disorder (with the notable exceptions being quetiapine,[10][11][12][13] olanzapine[14][15][16] and possibly asenapine[17]) as a monotherapy, even though the majority of atypical antipsychotics are known to possess significant antimanic activity,[18] which is yet to be clearly demonstrated for lurasidone.